Despite Breakthroughs, No Hurry To Venture Into The Microbiome
This article was originally published in Start Up
Executive Summary
A few start-ups and their backers have begun to pursue therapeutics for diseases modulated by our commensal, or beneficial, microbial populations. But the science is too new, and the VC world too shaken, to spur a rush to invest.